Drugs / Sacubitril/valsartan
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04023227 | Dec 2019 → Mar 2025 | Chagas disease, heart failure | Novartis Pharmaceuticals | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-08-25 | Novartis Pharmaceuticals | Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode novartis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sacubitril/valsartan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04023227 ↗ |
| Action | Inhibit | “the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan” PMID 41335448 ↗ Jan 2026 |
| Route | Oral | “receiving oral treatment with 50, 100, or 200 mg, film-coated tablets” NCT04023227 ↗ |